BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Beijing Biotech BCMA/CD38 dual-target CAR-T readouts · AssetM
 emo
X-WR-CALDESC:Upcoming readouts of Beijing Biotech BCMA/CD38 dual-target CAR
 -T\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07523555-3375@assetmemo.bio
DTSTAMP:20261121T010844Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:Beijing Biotech BCMA/CD38 dual-target CAR-T: Phase 1/2 readout est.
  (NCT07523555)
DESCRIPTION:Beijing Biotech BCMA/CD38 dual-target CAR-T\, phase 1/2\, Multi
 ple Myeloma.\nStudy: Adaptive Dual-Target CAR-T Cells for Relapsed or Refr
 actory Hematologic Malignancies\nEstimated primary completion: 14 March 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/beijing-biotech-b
 cma-cd38-dual-target-car-t#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07523555
URL:https://assetmemo.bio/drug/beijing-biotech-bcma-cd38-dual-target-car-t#
 upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
